Introduction {#section1-2050313X18819601}
============

The Hirata disease, also known as insulin autoimmune syndrome (IAS), is an unusual cause of hypoglycaemia characterized by high serum levels of insulin and a significant increase of endogenous antibodies which bind insulin/proinsulin and/or insulin receptor.^[@bibr1-2050313X18819601][@bibr2-2050313X18819601]--[@bibr3-2050313X18819601]^

Described by Yukimasa Hirata in 1972,^[@bibr4-2050313X18819601]^ IAS is the third commonest cause of spontaneous hypoglycaemia in Japan, after Insulinoma and extrapancreatic tumours.^[@bibr5-2050313X18819601]^

IAS is closely related with HLA-DR4. In the Japanese population, HLA DRB1\*04:06 and DRB1\*04:03 (at lower level) are the alleles most frequently found in this clinical pattern.^[@bibr6-2050313X18819601]^

Viral infections^[@bibr7-2050313X18819601]^ and drugs composed of sulphur/sulfhydryl groups such as methimazole,^[@bibr8-2050313X18819601]^ captopril, D-penicillamine, mercaptans, clopidogrel, imipenem, albumin and diltiazem have been considered as the potential factors inducing IAS.^[@bibr9-2050313X18819601]^ In several cases, IAS has been described in patients affected by other autoimmune disorders, such as autoimmune thyroiditis, membrano-proliferative glomerulo-nephritis and rheumatoids arthritis.^[@bibr10-2050313X18819601][@bibr11-2050313X18819601][@bibr12-2050313X18819601]--[@bibr13-2050313X18819601]^

In 2003, at the Kyushu local meeting of the Japan Diabetes Society, Hashinaga T. et al. reported a clinical case of IAS due to an additional sulfhydryl drug defined α-lipoic acid (ALA). In the recent years, an increase in cases of ALA-induced IAS has been described. IAS related to ALA administration has been reported most frequently in Japanese and Koreans subjects. Recently, seven new cases have been described in Italian patients.

We report a case of IAS induced by ALA in an Argentine woman who referred to our Department.

Furthermore, we provide a literature review of all the cases of IAS due to ALA administration, in order to open a comprehensive overview of the characteristics of this unusual disease.

Case {#section2-2050313X18819601}
====

A 66-year-old female referred to the Emergency Room for malaise and sweating. Laboratory findings showed low blood glucose level (2.56 mmol/L). She was admitted in our Department to study deeply the cause of hypoglycaemia. Informed consent was obtained.

Her clinical anamnesis was negative. Recently, due to joint pain, she started therapy with ALA (800 mg/day) for 1 month and, after a suspension of 15 days, she further continued for 10 days. Two weeks before the admission in our hospital, she discontinued this therapy due to repeated episodes of hand tremor and hunger that appeared 3--4 h after a meal. Furthermore, these symptoms regressed after sugar ingestion.

There was no family history of autoimmune or endocrine disorders.

The body weight was 72.55 kg and height was 170 cm (Body Mass Index 25.1 kg/m^2^). At admission, heart rate was 84/min and blood pressure 120/80 mmHg. The patient was conscious and oriented. Clinical chest and heart exams were negative. She had no thyroid goitre, acanthosis, skin tags or clinical and serological evidence of underlying autoimmune disease. Neurological findings were normal.

Laboratory values showed normal results except for blood glucose levels: 3.8 mmol/L (n.v. 4.0--5.9 mmol/L), high level of serum insulin: 1116.5 pmol/L (n.v. \< 174 pmol/L), inappropriately high level of C-peptide (1.81 nmol/L, n.v. 0.3--2.36). [Table 1](#table1-2050313X18819601){ref-type="table"} shows laboratory data on admission.

###### 

Results of laboratory test on admission.

![](10.1177_2050313X18819601-table1)

  Analyte                                           Patient's value   Reference range
  ------------------------------------------------- ----------------- -----------------
  Red blood count (×10^6)^                          4.6               (3.5--5.2)
  Haemoglobin (gr/dL)                               13.4              (12--16)
  Haematocrit (%)                                   41.3              (34.5--52)
  White blood count (/mm^3^)                        9.830             (4.3--10.8)
  Platelet count (×10^3^)                           335               (150--450)
  Creatinine (μmol/L)                               63.64             (48.62--97.24)
  Blood urea nitrogen (mg/dL)                       46                (15--50)
  Uric acid (mg/dL)                                 3.7               (2.4--5.7)
  Sodium (mEq/L)                                    140               (133--145)
  Potassium (mEq/L)                                 4.8               (3.3--5.1)
  Albumin (gr/L)                                    30                (34--48)
  Aspartate aminotransferase (IU/L)                 18                (6--24)
  Alanine aminotransferase (IU/L)                   35                (13--45)
  γ-glutamyl transpeptidase (IU/L)                  62                (5--55)
  C-reactive protein (mg/L)                         \<0.100           (0--3)
  Tissue transglutaminase antibodies (IgA; IU/mL)   2.02              (\<9)
  Deamidated gliadin peptide antibodies (IgG; IU)   \<2.8             (\<20)
  Deamidated gliadin peptide antibodies (IgA; IU)   \<5.2             (\< 20)
  Anti-endomysial antibodies (IgG)                  Negative          
  Anti-endomysial antibodies (IgA)                  Negative          
  Antiadrenal antibodies                            Negative          
  Anti-TPO antibodies (kIU/L)                       15                (0--35)
  Anti-insulin antibodies (UI/mL)                   271               (0--0.40)
  Fasting plasma glucose (mmol/L)                   3.8               (4--5.9)
  Immunoreactive insulin (pmol/L)                   1116.50           (21.52--143.5)
  C-peptide (nmol/L)                                1.81              (0.3--2.36)
  HbA1c (mmol/mol)                                  39                (23--42)
  Prolactin (nmol/L)                                0.38              (0.122--1.27)
  TSH (mIU/L)                                       3.13              (0.35--4.5)
  ACTH (pmol/L)                                     5.08              (0--10.12)
  i-PTH (pmol/L)                                    4.8               (1.49--7.64)
  25-OH-Vitamin D (nmol/L)                          61.4              (\>74.88)
  GH (μg/L)                                         2.0               (0.01--10)

TSH: thyroid-stimulating hormone; TPO: thyroperoxidase; ACTH: adrenocorticotrophic Hormone; i-PTH: intact-parathyroid hormone; GH: growth hormone; HbA1c: glycated haemoglobin.

An oral glucose tolerance test performed over 240 min showed basal glucose value of 3.88 mmol/L, a peak of 6.9 mmol/L at 120 min and a nadir of 2.33 mmol/L at 240 min.

Therefore, we performed enzyme immunoassay to obtain a quantitative determination of IgG autoantibodies to insulin in human serum (MediZym, Autoantibodies to Insulin enzyme-linked immunosorbent assay (ELISA) Assay Kit, MEDIPAN). High titre of insulin antibodies (271 U/mL, n.v. \< 0.4) had been detected.

We repeated blood sampling during a symptomatic episode of hypoglycaemia that confirmed the above-mentioned data: low blood glucose level (2.39 mmol/L), high levels of serum insulin (1971.55 pmol/L), inappropriately high levels of C-peptide (2.36 nmol/L) and high levels of insulin antibodies (274.78 IU/mL).

The 72-h fasting test was not performed due to the need for intravenous glucose support during the repeated and frequent hospital episodes of hypoglycaemia.

Abdominal computer tomography and Octreoscan scintigraphy excluded the presence of Insulinoma.

HLA-DNA typing identified DRB1\*04:03.

Patient required continuous *iv* 5% dextrose for 10 days. No further episodes of hypoglycaemia occurred. A diet with fractionated meals, composed of high-fibre foods and poor or fast-acting carbohydrate, was prescribed.

[Figure 1](#fig1-2050313X18819601){ref-type="fig"} shows blood glucose, insulin levels and antibodies levels during the hospitalization and follow-up.

![Blood glucose, serum insulin levels and antibodies titre during the hospitalization and follow-up period.](10.1177_2050313X18819601-fig1){#fig1-2050313X18819601}

Discussion {#section3-2050313X18819601}
==========

In most cases, IAS appears a few weeks after the administration of a drug containing sulfhydryl group.

The reducing activity of these compounds promotes the dissociation of the insulin S-S binding and exposes the insulin α chain to the antigen-presenting cells.^[@bibr14-2050313X18819601]^

The amino acid sequence Ile-Leu-Gln, contained in the insulin α chain, has a strong affinity for DRB1\*04:06 molecule.^[@bibr14-2050313X18819601]^ Another peptide localized from no.8 to no.17 of the insulin α chain (TSICSLYQLE) shows a high affinity with this molecule. This amino acid sequence is able to stimulate the T cells of DRB1\*04:06-positive patients, leading to the synthesis of polyclonal insulin autoantibodies.^[@bibr14-2050313X18819601],[@bibr15-2050313X18819601]^

In 2003, Hashinaga T. et al. reported an IAS clinical case due to an additional sulfhydryl drug, namely ALA.

ALA, also called thioctic acid, is a compound with a strong reductive effect.^[@bibr16-2050313X18819601]^

The antioxidant properties of α-lipoic acid play an essential role in the treatment of diabetic peripheral neuropathic pain.^[@bibr17-2050313X18819601]^ It is well known that the overproduction of reactive oxygen species is a common factor in the pathogenesis of atherosclerosis, diabetes mellitus and hypertension.

Furthermore, ALA is widely used as a health supplement for dieting and antiaging. In the past 20 years, ALA is often used as a dietary supplement in Japan. In these years, several cases of IAS have been reported and, after methimazolo, ALA has been considered the main cause of this syndrome.^[@bibr18-2050313X18819601]^ [Table 2](#table2-2050313X18819601){ref-type="table"} shows a summary of ALA-induced IAS cases described from 2003 to May 2018.^[@bibr13-2050313X18819601],[@bibr18-2050313X18819601][@bibr19-2050313X18819601][@bibr20-2050313X18819601][@bibr21-2050313X18819601][@bibr22-2050313X18819601]--[@bibr23-2050313X18819601]^ The majority of cases reported in the table have been presented exclusively in scientific meetings. Overall, 27 cases of Hirata disease due to ALA administration has been documented: 18 in Japan, 7 in Italy and 2 in Korea. In 23 patients, HLA-DNA typing has been reported. A total of 13 of 17 Asiatic patients had the HLA-DRB1\*04:06 allele compared with only 3 Asiatic patients with DRB1\*04:03. All Caucasian patients were Italian, in six of those HLA-DRB1\*04:03 was identified while HLA- DRB1\*04:06 was isolated in two cases.

###### 

α-lipoic acid-induced insulin autoimmune syndrome reported from 2003 to December 2016.

![](10.1177_2050313X18819601-table2)

  -----------------------------------------------------------------------------------
  No.   Age   Sex   Insulin (pmol/L)   Country   Author             Year   HLA-DRB1
  ----- ----- ----- ------------------ --------- ------------------ ------ ----------
  1     55    F     58.47              Japan     Hashinaga et al.   2003   0406

  2     44    F     3860.15            Japan     Furukawa et al.    2006   0406\
                                                                           0901

  3     67    F     5646.73            Japan     Kamiya et al.      2006   −

  4     66    M     4735.5             Japan     Nishikawa et al.   2006   0406

  5     49    F     1722↑              Japan     Takanashi et al.   2006   0406

  6     34    F     2870               Japan     Yoshioka et al.    2006   0406

  7     64    F     904                Japan     Kurashiki et al.   2006   DR4

  8     32    F     3.860              Japan     Ishida et al.      2007   0406

  9     34    F     3716.65            Japan     Nakajima et al.    2007   0406

  10    55    M     18.16              Japan     Takeuchi et al.    2007   0406

  11    36    F     464.94             Japan     Yoshida et al.     2007   −

  12    35    M     13.95              Japan     Sasaki et al.      2007   0406

  13    36    F     7139.13            Japan     Ogou et al.        2007   −

  14    40    F     30.996             Japan     Kudo et al.        2007   0403

  15    48    F     885.26             Japan     Matsui et al.      2007   0406

  16    45    F     94.997             Japan     Yamada et al.      2007   0403

  17    41    F     2047.03            Japan     Suzuki et al.      2007   −

  18    32    F     17.15              Japan     Yoshihiko et al.   2007   0406

  19    71    F     267.84             Korean    Chang et al.       2009   0406

  20    70    F     408.98             Italian   Bresciani et al.   2011   0406

  21    67    F     \> 7.175           Korean    Jeong et al.       2013   0406

  22    75    M     1714.83            Italian   Gullo et al.       2014   0406

  23    77    F     4018               Italian   Gullo et al.       2014   0403

  24    53    M     2085.43            Italian   Gullo et al.       2014   0403

  25    40    F     26561.85           Italian   Gullo et al.       2014   0403

  26    70    F     1607.2             Italian   Gullo et al.       2014   0403

  27    56    M     2001.83            Italian   Gullo et al.       2014   0403
  -----------------------------------------------------------------------------------

*Note:* The majority of cases reported in the table have been presented exclusively in scientific meetings and were not published.

We describe the case of an Argentine woman presenting episodes of hypoglycaemia related to the ingestion of ALA. The association of hypoglycaemia with extremely high levels of serum insulin was indicative of IAS.

Laboratory test showed inappropriately high level of C-peptide. It may be related to the cross-reactivity between C-peptide and proinsulin which may be immunologically counted and reported as 'free C-peptide'.^[@bibr1-2050313X18819601],[@bibr24-2050313X18819601],[@bibr25-2050313X18819601]^

Although in the reported cases the syndrome occurs mainly with neuroglycopenic symptoms, our patient experienced adrenergic symptoms that occurred 2--3 h after a meal. As reported in the scientific literature, also in our patient the symptoms appeared more than a month after starting therapy and disappeared spontaneously after 1 month of drug withdrawal.

HLA-DNA typing identified DRB1\*04:03. This finding confirms the implication of this allele in the genetic IAS predisposition also in not Asian population.

In our opinion, it is very suggestive that IAS related to ALA has been only described in the Asian population and in some Italian patients. The 'Allele Frequency Net Database' documented that HLADRB1\*04:06 has a high prevalence in the Japanese population (allele frequency: 0.0339) while it is less common in Italy (allele frequency: 0.001).^[@bibr26-2050313X18819601]^ HLADRB1\*04:03 is common among Caucasians and the allele frequency in Italy and Argentine are, respectively, 0.01 and 0.014. Nevertheless, analysing the allele frequency distribution, in countries with a similar prevalence of HLADRB1\*04:03 and common use of ALA (Germany, United States, etc.), no cases of Hirata disease related to ALA have been reported.

This epidemiological data is very interesting, although we have not clear evidence to explain it. In our opinion, there are some promoting or protective factors (genetic? environmental?) which can induce or swich off this autoimmune reaction. This aspect needs to be deeply investigated.

In our patient, hypoglycemic symptoms appeared more than a month after starting therapy and disappeared spontaneously after 1 month of drug withdrawal. After drug suspicion, the most effective therapy is usually the ingestion of several small amounts and avoiding meals with high glycaemic index carbohydrates. Otherwise, some patients required pharmacological intervention as alpha-glucosidase, corticosteroids, immunosuppressant and plasmapheresis. Alpha-glucosidase inhibitors, such as acarbose, delay the absorption of glucose, decreasing the hypersecretion of insulin.^[@bibr27-2050313X18819601]^ Another possible therapy is corticosteroids.^[@bibr8-2050313X18819601]^ Immunosuppressants and plasmapheresis may be used in not responsive patients.^[@bibr18-2050313X18819601]^

Conclusion {#section4-2050313X18819601}
==========

Nowadays, ALA therapy is widely used as a dietary and anti-aging supplement or as adjuvant therapy for symptomatic diabetic peripheral neuropathy; it is useful to know that, in patients with a genetic predisposition, this treatment could induce IAS. A prompt diagnosis is required and a targeted diet should be applied; in some cases a pharmacological therapy in needed.
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